Precore/Core promoter variants to predict significant fibrosis in both HBeAg positive and negative chronic hepatitis B

By  

LIVER INTERNATIONAL (ELECTRONIC), Vol. 35, Iss. 9, 2015-09 ,pp. : 2082-2089

John Wiley & Sons Inc

Access to resources Recommend Favorite

On‐treatment prediction of sustained response to peginterferon alfa‐2a for HBeAg‐negative chronic hepatitis B patients

By  

LIVER INTERNATIONAL (ELECTRONIC), Vol. 35, Iss. 5, 2015-05 ,pp. : 1540-1548

John Wiley & Sons Inc

Access to resources Recommend Favorite

Low HBeAg Serum Levels Correlate with the Presence of the Double A1762T/G1764A Core Promoter Mutation and a Positive Response to Interferon in Patients with Chronic Hepatitis B Virus Infection

By  

Intervirology, Vol. 46, Iss. 4, 2003-09 ,pp. : 222-226

Karger

Access to resources Recommend Favorite

HBsAg loss is not an ideal indicator for discontinuing treatment of HBeAg-negative chronic hepatitis B: a case report

By Dong Pei-ling   Zhang Xin   Zhao Wen-min   Ding Hui-guo  

Journal of Infection and Chemotherapy, Vol. 19, Iss. 6, 2013-12 ,pp. : 1188-1192

Springer Publishing Company

Access to resources Recommend Favorite

Association of IL28B polymorphisms with peginterferon treatment response in Chinese Han patients with HBeAg‐positive chronic hepatitis B

By  

LIVER INTERNATIONAL (ELECTRONIC), Vol. 35, Iss. 2, 2015-02 ,pp. : 473-481

John Wiley & Sons Inc

Access to resources Recommend Favorite